Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2011, Article ID 263725, 4 pages
http://dx.doi.org/10.1155/2011/263725
Case Report

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

1Department of Hematology, Hacettepe University Medical School, 06100 Ankara, Turkey
2Department of Genetics, Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey

Received 2 August 2011; Accepted 18 September 2011

Academic Editors: D. J. Allsup, S. Aref, E. Arellano-Rodrigo, and M.-C. Kyrtsonis

Copyright © 2011 B. Uz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Buyukasik, I. C. Haznedaroglu, and O. Ilhan, “Chronic myeloid leukemia: practical issues in diagnosis, treatment and follow-up,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 2, pp. 1–12, 2010. View at Google Scholar · View at Scopus
  2. M. Hayran, E. Koca, I. C. Haznedaroglu et al., “Predicting chronic leukaemias from assesment of complete peripheral blood counts,” Journal of International Medical Research, vol. 34, no. 6, pp. 640–647, 2006. View at Google Scholar · View at Scopus
  3. E. Koca and I. C. Haznedaroǧlu, “Imatinib mesylate and the management of chronic myeloid leukemia (CML),” Turkish Journal of Haematology, vol. 22, no. 4, pp. 161–172, 2005. View at Google Scholar
  4. V. Cobankara, B. Oran, D. Ozatli et al., “Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis,” Clinical and Applied Thrombosis/Hemostasis, vol. 7, no. 2, pp. 126–130, 2001. View at Google Scholar · View at Scopus
  5. N. Sayinalp, H. Çinar, A. Üner et al., “Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders,” Clinical and Laboratory Haematology, vol. 26, no. 4, pp. 265–268, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Akdoǧan, M. Sönmez, M. Yilmaz, A. Durmuş, E. Ovali, and S. B. Omay, “The development of chronic myelogenous leukemia in a patient with malign fibrous histiositom treated with radiotherapy: case report,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 18, no. 2, pp. 116–120, 2008. View at Google Scholar
  7. D. Ozatli, A. Timuragaoglu, G. Alanoglu, S. Dizlek, and N. Uysalgil, “BCR-ABL transcript level and neutrophil alkaline phosphatase activity in CML patients treated with imatinib,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 3, pp. 163–168, 2010. View at Google Scholar · View at Scopus
  8. E. Koca, M. Halil, Z. Adibelli et al., “Management of chronic myeloid leykemia (CML) in the pre-imatinib and imatinib era,” HAEMA, vol. 9, no. 5, pp. 663–671, 2006. View at Google Scholar · View at Scopus
  9. Y. Beyazit, M. Kekilli, and I. C. Haznedaroglu, “Second-generation BCR-ABL kinase inhibitors in CML,” The New England Journal of Medicine, vol. 363, no. 17, p. 1673, 2010. View at Google Scholar · View at Scopus
  10. G. Saydam, I. C. Haznedaroglu, Y. Temiz et al., “Retrospective evaluation of patients treated with dasatinib for Philadelphia positive leukemias: Turkish experience of 16 months,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 19, no. 4, pp. 195–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Kantarjian, S. O'Brien, M. Talpaz et al., “Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure,” Cancer, vol. 109, no. 8, pp. 1556–1560, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Puttini, A. M. L. Coluccia, F. Boschelli et al., “In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells,” Cancer Research, vol. 66, no. 23, pp. 11314–11322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Golas, K. Arndt, C. Etienne et al., “SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice,” Cancer Research, vol. 63, no. 2, pp. 375–381, 2003. View at Google Scholar · View at Scopus
  14. L. L. Remsing Rix, U. Rix, J. Colinge et al., “Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells,” Leukemia, vol. 23, no. 3, pp. 477–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Bektas, I. C. Haznedaroglu, Y. Buyukasik et al., “Dasatinib-induced tumor lysis syndrome and following hematologic remission in fibrotic blastic crisis of CML,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 2, pp. 13–16, 2010. View at Google Scholar · View at Scopus
  16. G. Kaygusuz, I. Kuzu, E. Akpinar, and A. Uysal, “Extramedullary hematopoiesis in the axillary lymph node in a patient with an accelerated phase of chronic myeloid leukemia,” Turkish Journal of Hematology, vol. 26, no. 1, pp. 40–41, 2009. View at Google Scholar · View at Scopus
  17. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Kantarjian, N. P. Shah, A. Hochhaus et al., “Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2260–2270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Saglio, D. W. Kim, S. Issaragrisil et al., “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2251–2259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Baccarani, J. Cortes, F. Pane et al., “Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 6041–6051, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Talpaz, N. P. Shah, H. Kantarjian et al., “Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias,” The New England Journal of Medicine, vol. 354, no. 24, pp. 2531–2541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. I. C. Haznedaroglu, E. Koca, S. Aksu et al., “The gray-zone concept, suboptimal response to imatinib, shall be removed from the ELN-CML recommendations,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 2, pp. 25–26, 2010. View at Google Scholar · View at Scopus
  23. M. Baccarani, G. Rosti, F. Castagnetti et al., “Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study,” Blood, vol. 113, no. 19, pp. 4497–4504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kantarjian and J. Cortes, “Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1512–1516, 2011. View at Publisher · View at Google Scholar
  25. D. Jones, D. Thomas, C. C. Yin et al., “Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors,” Cancer, vol. 113, no. 5, pp. 985–994, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Velev, J. Cortes, R. Champlin et al., “Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I,” Cancer, vol. 116, no. 15, pp. 3631–3637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Buyukasik, “Use of second generation tyrosine kinase inhibitors for second-line treatment of chronic myeloid leukemia after imatinib failure,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 4–9, 2011. View at Google Scholar
  28. A. S. Yavuz, “Long-term treatment of chronic myeloid leukemia,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 10–17, 2011. View at Publisher · View at Google Scholar
  29. Z. Gulbas, “Advanced-phase CML treatment and transplantation,” Uhod-UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement, pp. 18–23, 2011. View at Google Scholar
  30. F. Demirkan, “Current problems in the management of chronic myeloid leukemia in Turkey,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 24–28, 2011. View at Publisher · View at Google Scholar
  31. I. C. Haznedaroglu, M. Cetiner, and O. Ilhan, “The management of chronic myeloid leukemia in the era of second generation tyrosine kinase inhibitors,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 1–3, 2011. View at Publisher · View at Google Scholar